Pharmaceutical

Xencor gets grant for bispecific antibody for treating GPC3-associated cancers

Discover Xencor Inc's groundbreaking patent for novel GPC3 binding domains and bispecific antibodies targeting GPC3-associated cancers. Explore the innovative method for manufacturing these antibodies and their potential in cancer treatment.

Apr 5, 2024 - 00:00
Discover Xencor Inc's groundbreaking patent for novel GPC3 binding domains and bispecific antibodies targeting GPC3-associated cancers. Explore the innovative method for manufacturing these antibodies and their potential in cancer treatment.
Read the original article

Tags:

Previous Article

United Therapeutics gets grant for treatment of pulmonary hypertension using pro...

Next Article

Incyte gets grant for treatment of various cancers using specific compound

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Vertex pain drug results met with measured optimism — and questions — by observers and experts

STAT+: Vertex pain drug results met with measured optim...

Jan 30, 2024

Amgen in future of work: theme innovation strategy

Mar 5, 2024

Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy

Casgevy: Launch sequence and price analysis of the firs...

Aug 3, 2024